AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8333759 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast feeding
Number of subjects: 453
Study 8333759 — intervention group
Group type: COMPARATOR
Intervention: Control group (not breast fed)
Number of subjects: 453
Study 3567113 — intervention group
Group type: EXPERIMENTAL
Intervention: High alcohol condition
Number of subjects: 60
Study 3567113 — intervention group
Group type: EXPERIMENTAL
Intervention: Low alcohol condition
Number of subjects: 60
Study 3567113 — intervention group
Group type: COMPARATOR
Intervention: Placebo condition
Number of subjects: 60
Study 3567113 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall alcohol effect
Number of subjects: 60
Study 2598970 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous nicardipine (D3 nicardipine)
Number of subjects: 6
Study 2598970 — intervention group
Group type: COMPARATOR
Intervention: Intravenous unlabelled nicardipine (D0 nicardipine)
Number of subjects: 6
Study 30972654 — intervention group
Group type: EXPERIMENTAL
Intervention: Discrete Trial Training (DTT)
Number of subjects: 0
Study 30972654 — intervention group
Group type: EXPERIMENTAL
Intervention: Pivotal Response Training (PRT)
Number of subjects: 0
Study 28279316 — intervention group
Group type: EXPERIMENTAL
Intervention: COMBO Dual Therapy Stent
Number of subjects: 60
Study 28279316 — intervention group
Group type: COMPARATOR
Intervention: Cobalt-Chromium Everolimus-Eluting Stent (CoCr EES)
Number of subjects: 60
Study 28279316 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study 25998206 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg milnacipran twice daily
Number of subjects: 46
Study 25998206 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 23040140 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonorgestrel-releasing intrauterine system (LNG-IUS)
Number of subjects: 163
Study 21744962 — intervention group
Group type: EXPERIMENTAL
Intervention: Couples intervention
Number of subjects: 44
Study 21744962 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual intervention
Number of subjects: 44
Study 21744962 — intervention group
Group type: COMPARATOR
Intervention: Individual diabetes education
Number of subjects: 44
Study 18754014 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral sterile water (up to 50 ml kg(‐1) per day for 7 days)
Number of subjects: 214
Study 18754014 — intervention group
Group type: COMPARATOR
Intervention: Routine fluid management (control group)
Number of subjects: 214
Study 18754014 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral sterile water
Number of subjects: 214
Study 18754014 — intervention group
Group type: COMPARATOR
Intervention: Control infants
Number of subjects: 214
Study 16411579 — intervention group
Group type: EXPERIMENTAL
Intervention: Flow diagram of an RCT as a pedagogic aid
Number of subjects: 0
Study 15317632 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural therapy for insomnia (5 sessions, 7 weeks)
Number of subjects: 60
Study 15317632 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-help manual with telephone support (5 calls, 7 weeks)
Number of subjects: 60
Study 15317632 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control
Number of subjects: 60
Study 15317632 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual therapy
Number of subjects: 60
Study 15317632 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-help treatment
Number of subjects: 60
Study 15317632 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular users of sedative medication at baseline
Number of subjects: 60
Study 15317632 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural strategies
Number of subjects: 60
Study 10890311 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol 2 mg
Number of subjects: 16
Study 10890311 — intervention group
Group type: EXPERIMENTAL
Intervention: Amisulpride 50 mg
Number of subjects: 16
Study 10890311 — intervention group
Group type: EXPERIMENTAL
Intervention: Amisulpride 200 mg
Number of subjects: 16
Study 10890311 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 9058177 — intervention group
Group type: EXPERIMENTAL
Intervention: Anger-out (described loudly and quickly)
Number of subjects: 24
Study 9058177 — intervention group
Group type: EXPERIMENTAL
Intervention: Anger-in (relived inwardly)
Number of subjects: 24
Study 9058177 — intervention group
Group type: EXPERIMENTAL
Intervention: Mood-incongruent speech (described softly and slowly)
Number of subjects: 24
Study 8398006 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorthalidone
Number of subjects: 34
Study 8398006 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 29617851 — intervention group
Group type: EXPERIMENTAL
Intervention: Factor D (selenium/vitamin E/beta‐carotene)
Number of subjects: 29584
Study 29617851 — intervention group
Group type: EXPERIMENTAL
Intervention: Factor B (riboflavin/niacin)
Number of subjects: 29584
Study 29617851 — intervention group
Group type: EXPERIMENTAL
Intervention: Factor A (retinol/zinc)
Number of subjects: 29584
Study 29617851 — intervention group
Group type: EXPERIMENTAL
Intervention: Factor C (vitamin C/molybdenum)
Number of subjects: 29584
Study 29617851 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors C and D
Number of subjects: 29584
Study 28898959 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive training using a novel memory game on an iPad (n=21; 8 hours of gameplay over 4 weeks)
Number of subjects: 42
Study 28898959 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive training using a novel memory game on an iPad
Number of subjects: 42
Study 28898959 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=21; clinic visits as usual)
Number of subjects: 42
Study 26210642 — intervention group
Group type: EXPERIMENTAL
Intervention: ISIS‐APO(a)Rx 100 mg (6 doses)
Number of subjects: 47
Study 26210642 — intervention group
Group type: EXPERIMENTAL
Intervention: ISIS‐APO(a)Rx 200 mg (6 doses)
Number of subjects: 47
Study 26210642 — intervention group
Group type: EXPERIMENTAL
Intervention: ISIS‐APO(a)Rx 300 mg (6 doses)
Number of subjects: 47
Study 26210642 — intervention group
Group type: COMPARATOR
Intervention: Placebo (6 doses)
Number of subjects: 47
Study 26210642 — intervention group
Group type: EXPERIMENTAL
Intervention: ISIS‐APO(a)Rx (single doses 50-400 mg)
Number of subjects: 47
Study 26210642 — intervention group
Group type: COMPARATOR
Intervention: Placebo (single doses)
Number of subjects: 47
Study 23011409 — intervention group
Group type: EXPERIMENTAL
Intervention: CoQ(10)
Number of subjects: 40
Study 23011409 — intervention group
Group type: COMPARATOR
Intervention: Saline Solution (SS)
Number of subjects: 40
Study 20625691 — intervention group
Group type: EXPERIMENTAL
Intervention: Transplantation of mononuclear bone marrow cells (MBMC)
Number of subjects: 48
Study 20625691 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE genotype II
Number of subjects: 48
Study 20625691 — intervention group
Group type: COMPARATOR
Intervention: Matrix metalloproteinase‐2 triple genotype GGCCTT
Number of subjects: 48
Study 20625691 — intervention group
Group type: COMPARATOR
Intervention: I/D ACE polymorphism
Number of subjects: 48
Study 18202564 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Intermittent Training (HIT)
Number of subjects: 15
Study 18202564 — intervention group
Group type: COMPARATOR
Intervention: Repeated Sprint (RS)
Number of subjects: 15
Study 18202564 — intervention group
Group type: EXPERIMENTAL
Intervention: Both HIT and RS
Number of subjects: 15
Study 18202564 — intervention group
Group type: EXPERIMENTAL
Intervention: HIT
Number of subjects: 15
Study 17199209 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride varnish Fluoridin N5 (VOCO GmbH) applied every 6 months for 2 years
Number of subjects: 200
Study 17199209 — intervention group
Group type: EXPERIMENTAL
Intervention: Duraphat (Colgate Palmolive GmbH) applied every 6 months for 2 years
Number of subjects: 200
Study 17199209 — intervention group
Group type: COMPARATOR
Intervention: Control group (no fluoride varnish applications)
Number of subjects: 200
Study 12723759 — intervention group
Group type: EXPERIMENTAL
Intervention: Goshajinkigan, 7.5 g/day for 3 months
Number of subjects: 50
Study 12723759 — intervention group
Group type: COMPARATOR
Intervention: Placebo, 6.0 g/day for 3 months
Number of subjects: 50
Study 12723759 — intervention group
Group type: COMPARATOR
Intervention: Goshajinkigan, 7.5 g/day for 3 months (in non-diabetic subjects)
Number of subjects: 50
Study 10071469 — intervention group
Group type: EXPERIMENTAL
Intervention: Sandwich technique with resin‐modified glass‐ionomer cements
Number of subjects: 120
Study 10071469 — intervention group
Group type: COMPARATOR
Intervention: Base technique
Number of subjects: 120
Study 10071469 — intervention group
Group type: COMPARATOR
Intervention: Total bond technique
Number of subjects: 120
Study 10071469 — intervention group
Group type: EXPERIMENTAL
Intervention: Sandwich technique with compomers
Number of subjects: 120
Study 10071469 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitremer/Z100 sandwich restorations with a metal matrix
Number of subjects: 120
Study 7484484 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxybutynin plus bladder training
Number of subjects: 57
Study 7484484 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus bladder training
Number of subjects: 57
Study 7484484 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxybutynin
Number of subjects: 57
Study 7484484 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study 2127040 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline (2 X 600 mg/d)
Number of subjects: 120
Study 2127040 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline plus psychological training
Number of subjects: 120
Study 2127040 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 2127040 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline (2 X 600 mg/d) and psychological training
Number of subjects: 120
Study 7037184 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefuroxime (0.75 gm) every eight hours for five to ten days
Number of subjects: 58
Study 7037184 — intervention group
Group type: COMPARATOR
Intervention: Cefazolin (1 gm) every eight hours for five to ten days
Number of subjects: 58
Study 12202415 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular hCG
Number of subjects: 0
Study 12202415 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular progesterone
Number of subjects: 0
Study 12202415 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral estrogen added to progesterone
Number of subjects: 0
Study 30183430 — intervention group
Group type: EXPERIMENTAL
Intervention: Electromagnetic transduction therapy (EMTT) + Extracorporeal shock wave therapy (ESWT)
Number of subjects: 86
Study 30183430 — intervention group
Group type: COMPARATOR
Intervention: Extracorporeal shock wave therapy (ESWT) with sham-EMTT
Number of subjects: 86
Study 25744274 — intervention group
Group type: EXPERIMENTAL
Intervention: Paricalcitol (2 µg/day) combined with a liberal sodium diet (∼200 mmol Na(+)/day)
Number of subjects: 50
Study 25744274 — intervention group
Group type: EXPERIMENTAL
Intervention: Paricalcitol (2 µg/day) combined with dietary sodium restriction (target: 50 mmol Na(+)/day)
Number of subjects: 50
Study 25744274 — intervention group
Group type: COMPARATOR
Intervention: Placebo combined with a liberal sodium diet
Number of subjects: 50
Study 25744274 — intervention group
Group type: COMPARATOR
Intervention: Placebo combined with dietary sodium restriction
Number of subjects: 50
Study 25744274 — intervention group
Group type: EXPERIMENTAL
Intervention: Paricalcitol (2 µg/day)
Number of subjects: 50
Study 25744274 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 25744274 — intervention group
Group type: EXPERIMENTAL
Intervention: Sub-population (N = 9)
Number of subjects: 50
Study 24781567 — intervention group
Group type: EXPERIMENTAL
Intervention: Light sedation (BIS >80)
Number of subjects: 2
Study 24781567 — intervention group
Group type: COMPARATOR
Intervention: Deep sedation (BIS approximately 50)
Number of subjects: 2
Study 21823994 — intervention group
Group type: EXPERIMENTAL
Intervention: Superficial heat
Number of subjects: 34
Study 21823994 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold therapy
Number of subjects: 34
Study 21823994 — intervention group
Group type: EXPERIMENTAL
Intervention: Heating pad
Number of subjects: 34
Study 21823994 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast therapy
Number of subjects: 34
Study 21823994 — intervention group
Group type: COMPARATOR
Intervention: Rest
Number of subjects: 34
Study 20551461 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg semapimod intravenously for 1 day with placebo for 2 days
Number of subjects: 152
Study 20551461 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg semapimod intravenously for 3 days
Number of subjects: 152
Study 20551461 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 152
Study 20551461 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative dosing of semapimod > or = 360 mg
Number of subjects: 152
Study 19099570 — intervention group
Group type: EXPERIMENTAL
Intervention: Tablets
Number of subjects: 645
Study 19099570 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle changes (diet)
Number of subjects: 645
Study 19099570 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga
Number of subjects: 645
Study 19099570 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 645
Study 19099570 — intervention group
Group type: EXPERIMENTAL
Intervention: Suppositories
Number of subjects: 645
Study 15688090 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute phenylalanine and tyrosine depletion (APTD)
Number of subjects: 20
Study 15688090 — intervention group
Group type: COMPARATOR
Intervention: Placebo amino acid drinks
Number of subjects: 20
Study 11830525 — intervention group
Group type: EXPERIMENTAL
Intervention: Δ13 present
Number of subjects: 325
Study 11830525 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN treatment among patients with Δ13
Number of subjects: 325
Study 9835524 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (500 mg twice a day)
Number of subjects: 24
Study 9835524 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 7857216 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotalol 320 mg/po/d
Number of subjects: 18
Study 7857216 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 7857216 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotalol 320 mg/po/d in MRVT
Number of subjects: 18
Study 7857216 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotalol
Number of subjects: 18
Study 2632716 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (0.75 g/kg body weight, diluted in orange juice)
Number of subjects: 7
Study 2632716 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 7
Study 1104043 — intervention group
Group type: EXPERIMENTAL
Intervention: Early cholecystectomy
Number of subjects: 32
Study 1104043 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment
Number of subjects: 32
Study 31636806 — intervention group
Group type: EXPERIMENTAL
Intervention: L-carnitine-L-tartrate 1500 mg per day (n = 11)
Number of subjects: 20
Study 31636806 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 9)
Number of subjects: 20
Study 28286306 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryopreserved amniotic membrane (AM) transplant during strabismus reoperation
Number of subjects: 30
Study 28286306 — intervention group
Group type: COMPARATOR
Intervention: Control group (no AM wrap)
Number of subjects: 30
Study 26523787 — intervention group
Group type: EXPERIMENTAL
Intervention: Housing First intervention (At Home/Chez Soi project)
Number of subjects: 14
Study 23151422 — intervention group
Group type: EXPERIMENTAL
Intervention: US-guided technique
Number of subjects: 104
Study 23151422 — intervention group
Group type: COMPARATOR
Intervention: Doppler-assisted technique
Number of subjects: 104
Study 21615472 — intervention group
Group type: EXPERIMENTAL
Intervention: Imiquimod 5% cream applied to half of each IH once every other night for 16 weeks
Number of subjects: 44
Study 21615472 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated half of IH)
Number of subjects: 44
Study 19629021 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 17285204 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 125
Study 17285204 — intervention group
Group type: EXPERIMENTAL
Intervention: Tropisetron 0.5 mg/m2
Number of subjects: 125
Study 17285204 — intervention group
Group type: EXPERIMENTAL
Intervention: Tropisetron 1.0 mg/m2
Number of subjects: 125
Study 17285204 — intervention group
Group type: EXPERIMENTAL
Intervention: Tropisetron 1.5 mg/m2
Number of subjects: 125
Study 17285204 — intervention group
Group type: EXPERIMENTAL
Intervention: Tropisetron 2.0 mg/m2
Number of subjects: 125
Study 17285204 — intervention group
Group type: EXPERIMENTAL
Intervention: Tropisetron (all doses)
Number of subjects: 125
Study 17285204 — intervention group
Group type: EXPERIMENTAL
Intervention: Tropisetron (0.5, 1.0, 1.5, 2.0 mg/m2)
Number of subjects: 125
Study 17285204 — intervention group
Group type: EXPERIMENTAL
Intervention: Tropisetron (0.5 mg/m2)
Number of subjects: 125
Study 15591855 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (1 mg/kg)
Number of subjects: 34
Study 15591855 — intervention group
Group type: COMPARATOR
Intervention: Etomidate (0.2 mg/kg)
Number of subjects: 34
Study 11414005 — intervention group
Group type: EXPERIMENTAL
Intervention: Contextual version of Wason's selection task
Number of subjects: 0
Study 11414005 — intervention group
Group type: COMPARATOR
Intervention: Abstract version of Wason's selection task
Number of subjects: 0
Study 11414005 — intervention group
Group type: EXPERIMENTAL
Intervention: Wason's selection task with negatives
Number of subjects: 0
Study 9429523 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal wash
Number of subjects: 66
Study 9429523 — intervention group
Group type: COMPARATOR
Intervention: Nasopharyngeal wash
Number of subjects: 66
Study 7712670 — intervention group
Group type: EXPERIMENTAL
Intervention: R-oxprenolol
Number of subjects: 8
Study 7712670 — intervention group
Group type: EXPERIMENTAL
Intervention: S-oxprenolol
Number of subjects: 8
Study 7712670 — intervention group
Group type: EXPERIMENTAL
Intervention: R-oxprenolol glucuronide
Number of subjects: 8
Study 7712670 — intervention group
Group type: EXPERIMENTAL
Intervention: S-oxprenolol glucuronide
Number of subjects: 8
Study 7712670 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of R- and S-oxprenolol glucuronides
Number of subjects: 8
Study 2545455 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled salbutamol (100 micrograms to 4000 micrograms)
Number of subjects: 7
Study 2545455 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 2545455 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled salbutamol (500 micrograms and above)
Number of subjects: 7
Study 2545455 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled salbutamol
Number of subjects: 7
Study 144508 — intervention group
Group type: EXPERIMENTAL
Intervention: High doses of sodium aurothiomalate (150 mg weekly)
Number of subjects: 47
Study 144508 — intervention group
Group type: COMPARATOR
Intervention: Conventional doses of sodium aurothiomalate (50 mg weekly)
Number of subjects: 47
Study 31283023 — intervention group
Group type: EXPERIMENTAL
Intervention: LGVS (right vestibular stimulation)
Number of subjects: 36
Study 31283023 — intervention group
Group type: COMPARATOR
Intervention: Sham (placebo stimulation)
Number of subjects: 36
Study 28002208 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized follow-up
Number of subjects: 112
Study 28002208 — intervention group
Group type: COMPARATOR
Intervention: Conventional follow-up
Number of subjects: 112
Study 25396334 — intervention group
Group type: EXPERIMENTAL
Intervention: 70 kVp/30 mL CCTA
Number of subjects: 150
Study 25396334 — intervention group
Group type: COMPARATOR
Intervention: 80 kVp/60 mL CCTA
Number of subjects: 150
Study 25396334 — intervention group
Group type: COMPARATOR
Intervention: 100 kVp/60 mL CCTA
Number of subjects: 150
Study 22994579 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutraceutical combination with Orthosiphon stamineus
Number of subjects: 30
Study 22994579 — intervention group
Group type: COMPARATOR
Intervention: Nutraceutical combination without Orthosiphon stamineus
Number of subjects: 30
Study 19804400 — intervention group
Group type: EXPERIMENTAL
Intervention: Migraineurs (n=50)
Number of subjects: 88
Study 19804400 — intervention group
Group type: COMPARATOR
Intervention: Controls (n=38)
Number of subjects: 88
Study 19183308 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat meal (2 g fat, 320 kcal)
Number of subjects: 7
Study 19183308 — intervention group
Group type: COMPARATOR
Intervention: High-fat meal (38 g fat, 640 kcal)
Number of subjects: 7
Study 15996257 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab
Number of subjects: 16
Study 15996257 — intervention group
Group type: COMPARATOR
Intervention: No infliximab
Number of subjects: 16
Study 12562740 — intervention group
Group type: EXPERIMENTAL
Intervention: Comorbid personality disorder
Number of subjects: 670
Study 10690130 — intervention group
Group type: EXPERIMENTAL
Intervention: DCLHb 50 mg kg‐1 i.v.
Number of subjects: 34
Study 10690130 — intervention group
Group type: EXPERIMENTAL
Intervention: DCLHb 100 mg kg‐1 i.v.
Number of subjects: 34
Study 10690130 — intervention group
Group type: EXPERIMENTAL
Intervention: DCLHb 200 mg kg‐1 i.v.
Number of subjects: 34
Study 8556095 — intervention group
Group type: EXPERIMENTAL
Intervention: Medically unexplained constipation
Number of subjects: 0
Study 8556095 — intervention group
Group type: COMPARATOR
Intervention: Other functional bowel symptoms (diarrhea, bloating, abdominal pain)
Number of subjects: 0
Study 8556095 — intervention group
Group type: COMPARATOR
Intervention: Major depression and panic disorder
Number of subjects: 0
Study 1695298 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine (2.5‐5.0 mg b.i.d.)
Number of subjects: 800
Study 1695298 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide (12.5‐25 mg b.i.d.)
Number of subjects: 800
Study 316459 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 30
Study 316459 — intervention group
Group type: EXPERIMENTAL
Intervention: Codeine
Number of subjects: 30
Study 316459 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Number of subjects: 30